DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 115 filers reported holding DENALI THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.32 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $212,572 | -32.3% | 10,304 | -3.1% | 0.01% | -30.0% |
| Q2 2023 | $313,957 | +20.2% | 10,639 | -6.2% | 0.02% | +25.0% |
| Q1 2023 | $261,251 | +27.9% | 11,339 | +54.4% | 0.02% | +45.5% |
| Q4 2022 | $204,209 | -52.4% | 7,343 | -23.6% | 0.01% | 0.0% |
| Q4 2021 | $429,000 | +41.6% | 9,610 | +59.8% | 0.01% | +37.5% |
| Q3 2021 | $303,000 | -22.5% | 6,012 | +20.7% | 0.01% | -33.3% |
| Q2 2021 | $391,000 | +58.3% | 4,983 | +68.9% | 0.01% | +100.0% |
| Q4 2020 | $247,000 | -24.2% | 2,950 | -67.6% | 0.01% | -62.5% |
| Q3 2020 | $326,000 | +23.5% | 9,100 | -16.6% | 0.02% | +6.7% |
| Q2 2020 | $264,000 | +169.4% | 10,909 | +158.0% | 0.02% | +150.0% |
| Q1 2019 | $98,000 | +139.0% | 4,229 | +113.9% | 0.01% | +100.0% |
| Q4 2018 | $41,000 | – | 1,977 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $298,165,000 | 48.02% |
| Bratton Capital Management, L.P. | 953,035 | $14,600,000 | 28.53% |
| Flagship Pioneering Inc. | 8,005,747 | $122,648,000 | 6.71% |
| Casdin Capital, LLC | 650,000 | $9,958,000,000 | 1.03% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $67,568,000 | 0.50% |
| MARK ASSET MANAGEMENT LP | 68,864 | $1,055,000 | 0.26% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,507 | $345,000 | 0.26% |
| Artal Group S.A. | 400,000 | $6,128,000 | 0.25% |
| PIER 88 INVESTMENT PARTNERS LLC | 40,610 | $622,000 | 0.24% |
| HAMILTON LANE ADVISORS LLC | 30,948 | $474,000 | 0.20% |